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Abstract 
Introduction: The application of light as a stimulus in pharmaceutical systems and 
the associated ability to provide precise spatiotemporal control over location, 
wavelength and intensity, allowing ease of external control independent of 
environmental conditionals, has led to its increased use.  Of particular note is the use 
of light with photosensitisers. 
Areas covered: Photosensitisers are widely used in photodynamic therapy to cause a 
cidal effect towards cells on irradiation due to the generation of reactive oxygen 
species.  These cidal effects have also been employed to treat infectious diseases.  
The effects and benefits of photosensitisers in the treatment of such conditions are 
still being developed and further realised, with the design of novel delivery 
strategies.  This review provides an overview of the realisation of the 
pharmaceutically relevant uses of photosensitisers both in the context of current 
research, and in terms of current clinical application, and looks to the future 
direction.   
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Expert opinion: Substantial advances have been and are being made in the use of 
photosensitisers.  Of particular note are their antimicrobial applications, due to 
absence of resistance that is so frequently associated with conventional treatments.  
Their potency of action, and the ability to immobilise to polymeric supports is 
opening a wide range of possibilities with great potential for use in healthcare 
infection prevention strategies. 
 
 
1. Introduction  
 
Light and its benefits have long been studied by many different disciplines, and its 
use has been extended to the initiation and facilitation of reactions with benefit to 
health when applied to pharmaceutical and antimicrobial applications.  This review 
provides an overview of the use of light in conjunction with photosensitisers, and the 
progress that has been made from initial experimentation to clinical application and 
commercialisation of photosensitising systems. 
 
2.  Photodynamic therapy 
 
It has long been known that light can be used in conjunction with photoreactive 
plant-based compounds for medicinal benefit, most notably for skin 
hyperpigmentation.  Ancient Egyptians, from as early as 2000 B.C., used the juice of 
furocoumarin-containing Ammi majus to topically treat patches of vitiligo, followed 
by sun exposure, and the ancient Indian Ayurvedic system of medicine describes the 
use of seeds from the psoralen-containing Psoralea corylifolia to treat leucoderma 
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[1]. Phototherapy, whereby light is applied to the body to cause a change, often due 
to absorption by photosensitive compounds within the body, was then, and still is, 
used as a medical treatment for a number of conditions.  In the 1950s, neonatal 
jaundice was treated with the application of blue light, with the probable mechanism 
of action being realised substantially more recently as the cis-trans isomerisation 
around one of the bonds in bilirubin [2].  Its use in acne is attributed to the activation 
of a photosensitiser, coproporphyrin III in the bacterium Propionibacterium acnes [3, 
4].  Whilst phototherapy finds utility in some cases, it requires that the area to be 
treated is itself responsive to visible light, therefore limiting its use.  It is possible, 
however, to employ the use of exogenous photosensitive compounds that can be 
applied internally or externally, to allow treatment of disease.  This has been termed 
photodynamic therapy, or PDT. 
 
2.1  Mechanism of action of photosensitisers 
 
Oscar Raab, working alongside Herman von Tappenier, discovered the cidal effects 
of acridine dye on protozoal cells in 1900 [5, 6], and three years later von Tappenier 
published the effects of topically applied eoisin and light on skin cancer [7]. The 
photodynamic effect was due to dye-photosensitised photooxygenation of cellular 
components and peroxide accumulation [8].  The term ‘photodynamic therapy’ arose 
from photodynamische Wirkung (photodynamic effect), coined by von Tappeiner in 
1907 to describe the damage of living tissue by a combination of photosensitiser, 
visible light and oxygen [9].  The mechanism by which photosensitive compounds 
and dyes caused cell death was not discovered until over two decades later due to 
studies on the nature of oxygen and the processes occurring on photoactivation of 
! 4!
dyes.  Mulliken discovered that oxygen in the ground state occurred as a triplet [10, 
11], then in 1931, Kautsky proposed that singlet oxygen (1O2) formed due to energy 
transfer from the excited photosensitiser to oxygen [12], which allowed initiation of 
photodynamic reactions.  Further studies by a number of researchers developed the 
understanding of the processes involved and the currently held theory of the 
mechanism of action of photosensitisers [13-18], detailed in Figure 1.  The main 
photophysical and photochemical processes involved are thought to be similar for all 
photosensitisers.  
 
 
Figure 1.  Jablonski diagram of the pathways leading to photosensitisation following 
application of light to a photosensitiser, adapted from  [19].  When a photosensitiser 
absorbs light, it may undergo an electronic transition from the ground state ( !!! !!! ) to 
the singlet excited state ( !!! !!∗!), which is short-lived.  Some of the energy is then 
transferred, via intersystem crossing, to the relatively long-lived triplet excited state 
( !!! !!∗ !).  The molecule may then undergo electronic decay to the ground state, or either 
charge (type I reaction), or energy (type II reaction) may be transferred to a substrate 
or to molecular oxygen (a triplet state molecule, 3O2) respectively to generate reactive 
oxygen species.  The latter reaction is predominant.   Adapted from [98]. 
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Type I reactions lead to the generation of reactive oxygen species (ROS) due to 
interaction of the excited photosensitiser with a molecule in its immediate vicinity 
via hydrogen abstraction or electron transfer.  The ROS generated may be radical 
cations and anions, with superoxide anions (O2-) being formed from electron transfer 
to molecular oxygen.  The anions themselves are not particularly toxic to biological 
systems but can lead to the production of hydrogen peroxide via dismutation.  Via 
reactions initiated by O2-, hydroxyl radicals can then be formed, which interact with 
O2- to generate 1O2. 
 
Type II reactions involve energy transfer between an excited photosensitiser and 
molecular oxygen.  In the ground state, due to its two unpaired electrons with parallel 
spins, oxygen exists as a triplet (3O2) with a non-zero magnetic dipole.  The lowest 
lying excited states are singlet and it is this state that is easily formed in dye-
sensitised reactions (1O2).  Its lifetime is long in comparison to other ROS, estimated 
to be between 10-5 – 10-6 s [20].  1O2 is considered to have a predominant role in 
photodynamic cellular damage [21-23], mediating cytotoxic damage via damage to 
lysosomes, mitochondria, plasma membranes and golgi apparatuses [24]. 
 
2.2.  Treatment of human conditions with PDT 
 
Knowledge of the photophysics and photochemistry of photosensitisers has allowed 
the rational use of plant-based compounds, in addition to the synthetic design of 
photosensitisers, alongside application of light, in the treatment of human conditions.  
Usually the photosensitiser is either applied topically in the case of skin lesions, or is 
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injected and time is allowed for localisation in the site to be treated.  Visible light, at 
a wavelength appropriate for optimum photoactivation of the photosensitiser, is then 
applied.  For applications where treatment within deeper tissues is required, as is the 
case in many cancerous tumours, the photosensitiser often must absorb at a long 
wavelength, allowing the light applied to penetrate the body tissues.  Use of fibre 
optics and lasers, however, has allowed treatment of tumours deeper within the body.  
The advantage of PDT over a number of conventional treatments, in particular over 
conventional chemotherapeutic treatments employed in cancer therapy, is the ability 
to selectively localise and accumulate the photosensitiser in the tumour or damaged 
tissue to be treated, and to deliver light specifically to the relevant area, thus 
minimising collateral damage to normal tissue.  The precise mechanism of 
localisation is not known, but in tumours is thought to be related to the high vascular 
permeability of photosensitisers and their affinity for proliferating endothelial tissue, 
in addition to the reduced lymphatic drainage from tumours [25], and in some cases 
to photosensitiser binding to low-density lipoprotein (LDL) and the resultant uptake 
facilitated by tumour upregulation of LDL receptors [26].  As a result, particularly in 
cancer treatment, substantially reduced side effects are noted when compared with 
conventional chemotherapeutic drugs.  PDT, of course, is not without disadvantage, 
with prolonged skin photosensitivity and excessive damage at the treatment site 
being reported [24], but these effects are minor when compared to those resulting 
from the comparatively indiscriminate ablation of cells within the body during 
chemotherapy. 
 
PDT has shown success in various types of cancer, blindness due to age-related 
macular degeneration, and in skin actinic keratosis [27].  Whilst a large number of 
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photosensitisers have been researched and synthesised, a comparatively smaller 
number have been used clinically in disease treatment.  The structures of a number of 
photosensitisers currently used clinically in PDT are shown in Figure 2, with the 
majority belonging to the porphyrin group of photosensitisers. These include 
haematoporphyrin derivative (HpD), the most widely used marketed photosensitiser, 
which exists as a mixture of oligomers.  It is FDA approved for early and late 
endobronchial lesions, Barrett’s oesophagus, and oesophageal obstructing lesions.  It 
has also been used off-label for a variety of conditions, and has approval in many 
countries for the treatment of bladder, genitourinary and digestive tract cancers, as 
reviewed by Dougherty et al. [28].  High or complete responses in the FDA approved 
treatments have been reported [29-33], as has control of squamous and basal cell 
lesions and Kaposi sarcoma [34-36].  The great disadvantages of HpD are its lack of 
selectivity and prolonged photosensitivity, requiring patients to avoid sunlight for at 
least four weeks.  Although it concentrates mainly in the tissue to be treated, there is 
also an extensive normal tissue reaction, which can manifest as swelling of the skin 
or necrotic tissue slough, which can be life threatening [37].  Another widely used 
entity for PDT is 5-aminolevulinic acid (ALA).  ALA is not itself a photosensitiser, 
but a prodrug which is intracellularly metabolised to the photosensitiser 
protoporphyrin IX [38].  It, and the methylated ALA, M-ALA, have found use 
mainly in the treatment of skin lesions, with success reported against basal and 
squamous cell carcinoma, as reviewed by Klein et al. [39].  An ALA-containing 
plaster has recently been licenced by the MHRA for treatment of actinic keratosis on 
the face and head [40].  For a review of other photosensitisers currently marketed 
and used clinically, including temoporfin which poses as a potential replacement to 
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HpD in Europe, and some used in vetinary, reference can be made to Allison et al.  
[37]. 
 
 
 
 
 
 
Figure 2.  Examples of some photosensitisers clinically used in PDT.  
Haematoporphyrin derivative (a), ALA (b) and the photosensitiser to which it is 
intracellularly metabolised protoporphyrin IX (c), temoporfin (d), and 8-
methoxypsoralen (e). 
 
 
Non-porphyrin based photosensitisers are used, but to a lesser degree.  One example 
is the continued use of psoralens in the treatment of skin lesions.  Psoralen plus UVA 
light (320-400 nm), known as PUVA therapy was introduced in 1974 by Parrish et 
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al. [41], and is used for treatment of vitiligo, and also of psoriasis.  In the latter case, 
light is applied following oral administration of the psoralen, 8-methoxypsoralen, 
with the generated reactive oxygen species causing crosslinking of DNA, therefore 
preventing cell replication and plaque formation.  It must be noted that this does not 
treat the cause of the condition and therefore is not a curative intervention.  PUVA 
therapy appears to have declined in popularity as a psoriasis treatment in recent 
years, perhaps due to the increasing use of narrow-band UVB phototherapy (311-313 
nm).  Narrow-band UVB therapy does not require the administration of a 
photosensitiser or wearing of eye protection, and the nausea associated with 
psoralens is avoided; for this reason it is often preferred by patients.  Additionally, 
despite the comparatively more reliable and efficient clearing of psoriasis with 
PUVA, clinicians appear to tend towards UVB therapy due to concerns regarding the 
long term safety of PUVA following reports of cutaneous carcinoma [42].   
 
The pharmaceutical application of photosensitisers, has not been limited to the 
treatment of human disease.  Antimicrobial therapy plays a large role in the area of 
medicine and pharmaceuticals, and the use of light within this area has been found to 
be of great benefit.   
 
3.  Light-triggered antimicrobial systems 
 
3.1  Effects of light on microorganisms 
 
The discovery of the antibiotic, penicillin, in 1928 was one of the greatest 
breakthroughs in modern medicine, particularly in a culture where infection was 
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highly prevalent and often fatal.  Prior to this, however, came another accidental 
discovery, also with great and long-reaching repercussions.  In 1877, Downes and 
Blunt noted the appearance of cloudiness in sugar water placed on a windowsill in 
the shade but remained clear while in the sun, which microscopic examination 
showed to be due to bacterial growth in the solution in the shade [43].  Further 
studies on the effects of light on microorganisms were conducted in 1885 by Arloing  
[44-46] and Duclaux, who demonstrated the cidal effect of sunlight on Bacillus 
anthracis and Tyrothrix scaber respectively [47].  In 1892, Geisler used a prism and 
heliostat to demonstrate the lethality of sunlight and electric arc lamps to B. typhosus 
[48], and in doing so provided evidence that wavelengths of all parts of the spectrum, 
with the exclusion of red, could cause harm to bacteria.   In the same year, Marshall 
Ward demonstrated the UV/violet/blue portion of the spectrum primarily to have 
bactericidal action, conducting experiments with Bacillus anthracis [49].  At the end 
of the 19th century, Niels Finsen pioneered the use of UV light to cure lupis vulgaris 
in tuberculosis sufferers, and in doing so made aware the potential medical uses of 
light  [2].  A recent study, however, has suggested that the effective wavelength 
possible with his lenses may have been above 340 nm, thus activating endogenous 
porphyrins in Mycobacterium tuberculosis to effect treatment, rather than UV-
mediated bactericidal action [50].  Regardless of the mechanism, his invention was 
of great benefit, and certainly instrumental in the investigations of microbicidal 
effects of UV light.  The precise wavelength with the most potent bactericidal effect 
within the UV range was further investigated by Barnard and Morgan [51] and 
Newcomer [52], and eventually narrowed to 253.7 nm by Ehrismann and Noethling 
in 1932 [47].  
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The discovery of the germicidal effects of UV light led to its use in drinking water 
disinfection [47], and in disinfection of contact lenses [53], but more significantly for 
the present area is its use for sterilisation within healthcare environments.  As UV 
light cannot penetrate solid, light-absorbing materials, UV sterilisation within the 
hospital is mainly limited to inactivation of airborne or surface located 
microorganisms [54].   
 
For a number of microorganisms, including bacterial spores, UV light alone is often 
not sufficient to induce a cidal effect.  There are also dangers of skin and eye damage 
related to occupational exposure [55].  Constraining factors in the use of UV light in 
treatment of host-localised infections are the potential for adverse effects or lack of 
skin penetration.  The use of visible light, however, is of greater interest, and its use 
for broad-spectrum antimicrobial purposes is possible due to the availability and 
development of photosensitisers. 
 
3.2.  Photodynamic antimicrobial chemotherapy 
 
As discussed, the discovery of the cidal action of photosensitisers was first made in 
the field of microbiology by Raab [5].  The development of antibiotics in the 1940s 
however, stalled further research into the antimicrobial uses of photosensitisers, as 
bacteria could be effectively eradicated systemically and topically, with further 
development of antifungal, antiprotozoal and antimalarial agents.  When 
photosensitisers were rediscovered as antimicrobials, they were first applied to 
lesions caused by the herpes simplex virus, but safety concerns and claims of 
ineffectiveness halted the progress once again [56-59].  Increasing antibiotic 
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resistance, however, has driven the need to find alternative antimicrobials, and 
photosensitisers have become a more popular topic of research.  
 
Photodynamic antimicrobial chemotherapy (PACT) is based on PDT but applied 
specifically to microbial cells.  The underlying principle of PACT is that if live 
microbial cells can be selectively demonstrated by a particular dye, which is also 
photosensitive, then illumination of the stained microorganism should result in a 
cidal action towards that cell when in a biological environment or human subject  
[22].  Uptake of the photosensitiser by the challenge organism is usually required, 
occurring in a non-specific manner (i.e. not mediated by a photosensitiser-specific 
uptake mechanism), followed by application of light of the appropriate wavelength.  
While the uptake mechanism is not specific, due to the comparatively rapid uptake of 
photosensitisers by microbial cells, it has been found that a short drug-light interval 
is optimal for selective uptake by microbial cells over the mammalian host cells and 
tissue [60]. 
 
Reactive oxygen species are then generated within the bacterial cell on irradiation, 
with the photophysics proceeding in a similar manner to that presented in Figure 1.  
Due to the lipophilic nature of most photosensitisers used, they can localise in the 
lipid membranes of the bacterial cells.  The concentration of molecular oxygen in the 
lipid membranes is higher than in the surrounding aqueous phase, therefore 
favouring a type II mechanism of photodamage, and thus generation of 1O2 [61, 62]. 
1O2 is highly reactive and can initiate further oxidative reactions with many 
electrophilic materials including the unsaturated lipids of the bacterial cell 
membrane.  Oxidation of nucleic acid residues, mainly guanosine, leads to nucleotide 
! 13!
degradation, DNA strand breakage, and inhibition of replication [22].  The reactivity 
of singlet oxygen with organic molecules, however, is indiscriminate, therefore any 
macromolecule of the bacterial cell is a potential target.  This potential multiplicity 
of, and lack of specificity towards, targets makes the development of resistance by 
bacteria more difficult [63], and indeed despite a number of attempts to induce 
bacterial resistance with sub-lethal PACT, no resistant organisms have yet been 
reported [64-67], although upregulation of a heat-shock protein has been noted in 
some organisms [69, 70] .  This is of particular significance in light of a recent World 
Health Organisation (WHO) report highlighting the global problem of antibiotic 
resistance in bacteria [68].  A proportion of the cidal actions may also be related to 
the specific photosensitiser used, as this can determine the predominant 
photodynamic reaction (type I or II) occurring, and factors such as charge, 
lipophilicity, size and shape will influence their main site of interaction with and 
localisation within the microbial cell.  Cells in the logarithmic growth phase are more 
susceptible than those in the stationary phase [22].  Additional factors affecting cidal 
activity include the wavelength and intensity of light absorption, and the efficiency 
of production of 1O2 [71].  
 
A wide range of bacterial species have demonstrated sensitivity to photosensitiser-
mediated cidal treatment, including a number of antibiotic-resistant bacteria [72-75].  
Photosensitisers have been shown to be effective antifungal [76-78], antiviral [79], 
and sporicidal [80-83] agents, in addition to showing promise in the treatment of 
tropical diseases such as malaria [84-86] and leishmaniasis [87-90].   
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Although PACT is effective against a number of bacterial genera and species, there 
are differences in susceptibility due to differences in bacterial cell wall structure.  
Gram-negative bacteria are generally less sensitive than Gram-positive due to the 
possession of the outer membrane containing porins, lipopolysaccharides, and 
lipoproteins resulting in a densely packed negative charge.  This acts as a barrier to 
penetration, with only hydrophilic compounds with a molecular weight below 600-
700 Daltons able to diffuse through the porin channels [91, 92].  It has been 
suggested in a recent study that Gram-negative bacteria may be more susceptible to 
killing induced by type I activation of photosensitisers, leading to the generation of 
hydroxyl radicals, whilst Gram-positive may be more susceptible to 1O2 [93].  It is 
therefore possible that in cases where bacteria display lower susceptibility to 
photosensitisers, the choice of photosensitiser used may be governed by the pathway 
of generation of reactive oxygen species.  A number of photosensitisers, including 
the phenothiazinium dye methylene blue, have been noted to act via both pathways, 
producing both radicals and 1O2 [93].   
 
A number of methods have been successfully used to overcome reduced 
susceptibility due to permeability barriers.  One of the most straightforward is the 
imparting of a positive charge to the photosensitiser.  This approach has been found 
to produce broad-spectrum photosensitisers, resulting in inactivation of G+ and G- 
bacteria, in addition to viruses, fungi and parasites [79].  The majority of 
photosensitisers used in PACT are therefore cationic. 
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Two particular groups of photosensitiser have been heavily investigated for their 
antimicrobial actions – the porphyrins and phenothiaziniums.  The general structure 
of porphyrins is shown in Figure 3. 
 
 
Figure 3.  The structure of porphin, the parent compound on which porphyrins are 
based 
 
 
Photosensitisers of the porphyrin class have received increased attention as, due to 
their presence in natural systems, they generally do not possess cytotoxicity in the 
dark.  Furthermore, many possess long-lived triplet states, allowing for high quantum 
yields of 1O2, and they can be easily modified with substituents, metal ions and 
ligands to allow optimisation of their properties [94].  Accordingly, a number of 
synthetic porphyrins have been designed and tested to achieve efficient microbicidal 
activity. 
 
The general structure of phenothiazinium compounds is shown in Table 1. 
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Table 1.  Structure of a number of commercially available phenothiazinium 
photosensitisers used in PACT 
 
Phenothiaziniums have many favourable properties, conferring broad-spectrum 
antibacterial activity.  They are cationic at physiological pH, allowing targeting of 
the negatively charged bacterial membrane, and their lipophilicity allows for 
partitioning into the membrane environment.  These properties allow breach of the 
membrane as a barrier, and appear to enhance their efficacy against Gram-negative 
bacteria.  It has also been suggested that toluidine blue O may induce structural 
changes in the lipopolysaccharide of the Gram-negative membrane, further reducing 
its barrier function [95].  Methylene blue and toluidine blue O have been suggested 
to form neutral quinonemine intermediates in the lower pH of the membrane, thus 
promoting their uptake through the membrane, possibly followed by regeneration of 
the cationic species intracellularly [71].  The planar, cationic structure of this class of 
photosensitisers allows intercalation with DNA nucleosides, followed by photo-
oxidation, providing an important mechanism of phenothiazimium photoinduced cell 
 
Compound R1 R2 R3 R4 R7 R8 R9 
Methylene blue H H N(CH3)2 H N(CH3)2 H H 
Toluidine blue O H H NH2 H N(CH3)2 H H 
New methylene 
blue 
H CH3 NHEt H NHEt CH3 H 
Dimethyl 
methylene blue 
CH3 H N(CH3)2 H N(CH3)2 H CH3 
S
N
R1
R2
R3
R9
R8
R7
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death.  As with many photosensitisers, the primary sites of action of a given 
phenothiazinium can, however, differ between bacterial genera [22].  New methylene 
blue and new methylene blue N are effective against the Gram-negative bacterium 
Yersina enterocolitica which colonises red blood cell concentrates, conferring 
potential utility in blood disinfection [96], and as already mentioned, have 
demonstrated efficacy against antibiotic-resistant bacterial strains [73, 75]. 
 
3.3.  Clinically used PACT 
 
As with PDT, despite a wide research base and significant efforts in optimisation of 
photosensitiser design, only a small number have been used clinically for 
antimicrobial applications, but due to the success of published research, and 
increasing antibiotic resistance, it is anticipated that their clinical use will increase 
substantially over the coming years.  Those used are of the porphyrin and 
phenothiazinium class, and neutral red, in addition to a conjugate between 
chlorin(e6) and polyethylenimine  [79, 97].  The structure of neutral red is shown in 
Figure 4 .  
 
 
Figure 4.  Structure of neutral red 
 
Delivery of the photosensitiser to the target site also poses a challenge, and at present 
those used clinically are currently limited mainly to the topical treatment of localised 
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or dermatological infections (mainly ALA), or in dentistry (phenothiaziniums).  As 
will be discussed, however, advances in the design of polymeric carriers for 
photosensitisers are anticipated to change this pattern in the future.  
 
A summary of some infectious diseases that have been clinically treated with PACT 
is shown in Table 2. 
! 19!
Table 2.  A summary of some infectious diseases that have been clinically treated using PACT 
Infectious disease Site of infection Causative organism Photosensitiser References 
Acne vulgaris Skin and sebaceous 
glands 
P. acnes ALA 
Methylaminolevulinate 
Chlorophyll 
Indocyanine green 
 [98-103]  
 [104-106] 
 [107] 
 [108]  
Rosacea Skin Unknown ALA 
Methylaminolevulinate 
[109] 
[110] 
Periodontitis Dental pockets, gingival 
tissue 
Porphyromonas gingivalis, 
Fusobacterium nucleatum 
Phenothiazinium dyes including methylene 
blue 
[111-115] 
Peptic ulcer disease Stomach Helicobacter pylori ALA 
Endogeneous porphyrins 
[116] 
[117, 118] 
Generic localised infections Brain abscess Bacteria Haematoporphyrin [79] 
Onychomycosis Nails Trichophyton species ALA [88, 119, 120] 
Cutaneous Leishmaniasis Skin Protozoa ALA 
Methylene blue 
[121-123] [88] 
Herpes keratitis Cornea Herpes simplex virus Proflavine [124] 
Genital herpes Skin, mucous membranes Herpes simplex virus Methylene blue, neutral red, proflavine [58] 
Verruca vulgaris (common wart) Skin Human papilloma virus ALA [125-127] 
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As shown in Table 2, whilst applications have mainly been limited to topical 
treatments, PACT has allowed successful intervention in a large number of infectious 
diseases.  One of particular note is the treatment of acne vulgaris.  Acne vulgaris is 
not solely a microbiological issue, with many other contributing factors, however the 
presence and involvement of the bacterium P. acnes provides one mode of treatment. 
The haem biosynthetic pathway of ALA conversion to protoporphyrin IX is highly 
conserved across microorganisms [19], allowing a non-specific targeting of 
colonising microorganisms.  P. acnes is known to accumulate high levels of 
porphyrins, rendering it particularly susceptible to ALA-mediated photoinactivation.  
For a thorough review of the use of photosensitisers in acne treatment, reference can 
be made to Wainwright et al. [128]. 
 
Another area being increasingly explored, and gaining rapid support of dental 
clinicians is the treatment of dental infections.  Periodontitis is one of the most 
common bacterial diseases in humans, arising from the accumulation of plaque 
biofilms on the teeth and soft tissue of the mouth, and is frequently accompanied by 
inflammation of connective tissue and resorption of alveolar bone [79].  
Phenothiazinium photosensitisers are injected into the affected area, usually the dental 
pocket, followed by a short period of illumination using a fibre optic tip.  A number 
of companies have developed and marketed systems particularly for this use, and for 
treatment of infected root canals and tooth surfaces [129-131].  Considerable success 
has been demonstrated in the treatment of chronic [114, 115, 132-134], aggressive 
[67, 111, 113, 135], and HIV-associated [136] periodontitis in a number of patients, 
either as monotherapy or as an adjunct to conventional treatments, with results 
comparable to or superior to those of conventional treatments, and reduction of pain 
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and minimisation of the use of anaesthesia amongst the benefits.  The reported 
improvements in clinical parameters such as pocket depths are mainly short-term, 
with further study required to fully ascertain long-term benefits.   
 
A number of systems have been and are currently undergoing clinical trials for 
treatment of a variety of infections.  Methylene blue systems are undergoing clinical 
trials for reduction of resistant endotracheal tube biofilms [137], and for 
decolonisation of nasal MRSA [138], and photodisinfection treatment of chronic 
sinusitis [139], both developed by Ondine Biomedical.  HIV-associated oral 
candidiasis has also been successfully phototreated with methylene blue [140]. 
For a comprehensive description of clinical applications, readers are referred to 
reference [79]. 
 
3.3.1.  Decontamination of blood 
 
A number of disadvantages are associated with the use of conventional inactivation of 
pathogens in blood and blood products.  UV light has been shown to damage plasma 
components, and may generate free radicals in plasma proteins, although the latter 
may be circumvented by the concomitant addition of antioxidants.  Detergents cannot 
be used for blood disinfection due to potential damage to the erythrocyte cell 
membrane, and whilst physical methods, including filtration and washing, can remove 
extracellular contaminants, they are ineffective removal methods for intracellular 
pathogens [71].   Employing photodynamic inactivation of contaminating pathogens 
may afford a safer alternative. 
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Treatment of microorganisms within a human host poses a number of challenges, 
however it is possible to treat blood and blood products externally, prior to 
transfusion into a patient.  Blood and blood products may be infected with bacteria, 
viruses including the human immunodeficiency virus (HIV), protozoa, or fungi and 
require disinfection prior to transfusion [71, 96].  The use of photosensitisers as 
disinfecting agents is recognised, and methylene blue has been widely used by a 
number of blood transfusion services in the decontamination of blood plasma, with 
particular efficacy against viruses [22].  As it absorbs at 656 nm [71], activation is 
with long wavelength light, which is not absorbed by haemoglobin or plasma, and 
thus can penetrate to activate methylene blue.   
 
 
3.3.2.  Novel areas and strategies in PACT  
 
A number of photosensitisers and approaches to PACT have not yet been used 
clinically, but the findings of some recently published studies are of great interest and 
significance to the area of PACT, and are presented in the following sections. 
 
3.3.2.1.  Nebulised methylene blue for lung delivery  
 
Delivery of the light source to the area to be treated can be problematic.  A pilot study 
has been conducted, demonstrating nebulised delivery of methylene blue to a porcine 
CF lung and irradiation using a fibre optic light source, highlighting the ability to 
deliver a photosensitiser and light to the site of infection [141].  Antimicrobial 
susceptibility was not determined in this study, however previous studies have 
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demonstrated efficacy of PACT against lung pathogens, and the same group have 
assessed in a separate in vitro study the efficacy of methylene blue alone and in 
combination with antibiotics against Burkholderia cepacia, with positive results  
[142].  Due to the inherent resistance of B. cepacia to multiple antibiotics [143], this 
may provide a useful alternative.  Clinical studies are required to verify the utility of 
such an approach. 
 
3.3.2.2. Immobilised photosensitisers 
 
3.3.2.2.1.  Immobilisation on polymers 
 
As reviewed, traditional PACT mainly requires uptake of the photosensitiser by the 
microorganism being challenged.  Until recently, very few studies providing 
photoinactivation of microorganisms without the requirement for photosensitiser 
uptake had been published with application in pharmaceutical areas.  Successful 
immobilisation of photosensitisers onto a support allows delivery to areas previously 
inaccessible by solutions.  The contrast between the mechanism of action of 
conventional PACT and surface immobilised photosensitisers is shown in Figure 5. 
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Figure 5.  Comparison between the mechanism of conventional PACT (a) and surface-
immobilised photosensitisers (b).  Uptake of the photosensitiser is required by the 
bacterial cell in PACT, which then generates bactericidal reactive oxygen species such 
as 1O2 on irradiation.  With surface-immobilised photosensitisers, 1O2 is generated from 
the surface of the material, exerting a cidal action on approaching bacterial cells when 
within the required distance. In both (a) and (b), photosensitiser is shown in purple 
 
One of the earliest studies of immobilised photosensitisers was by Kautsky and de 
Bruijn who demonstrated that a solid impregnated with Rose Bengal generated what 
is now known to be 1O2 (cited in [144]).  Bonnett et al. in 1993 prepared polymer-
porphyrin films by impregnating regenerated cellulose films with porphyrins [144], 
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by covalently binding porphyrin to the cellulose then casting, and by co-polymerising 
porphyrin with cellulose before casting, and subsequently demonstrated 
photobactericidal effects towards S. aureus, Escherichia coli, Bacillus subtilis, and P. 
vulgaris [145].  Since then, only a handful of studies have been conducted, but these 
provide important information regarding the potential for such an approach clinically.   
 
A number of those published are related to work within the McCoy research group 
[20, 146, 147], whereby the photosensitiser is electrostatically localised at the surface 
of a polymer to prevent microbial adherence, with particular focus on ocular 
applications.  Generated 1O2 from the immobilised photosensitiser prevents bacterial 
adherence to the surface of the material, therefore preventing colonisation and biofilm 
formation.  As the lifetime of 1O2 is in the range of 10-5–10-6 seconds, the effective 
distance between the initial excitation event and cytotoxic damage is limited to a few 
micrometers, therefore preventing toxicity to normal tissue [20].  This is a sufficient 
distance to prevent bacterial adhesion, as reinforcement of adhesion to a surface is not 
thought to occur until a bacterium is within 1 nm of the surface [148].  High levels of 
surface localisation were achieved, coupled with promising antimicrobial activity 
against both Gram-positive and negative species.   
 
Krouit et al. published two studies on the development of covalently bound 
porphyrin-cellulose films, using protoporphyrin IX [149] and 
monopyridyltritolylporphyrin [150] respectively to produce photobactericidal films.  
In both studies, 1O2-mediated inactivation of S. aureus and E. coli was reported, 
however as this was measured by the presence or absence of colonies on seeded 
nutrient agar plates after contact with the films under irradiation, the initial bacterial 
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challenge and log reduction are unknown.  Also working with cellulose, but for 
applications as a surface coating is Wilson [151].  Toluidine blue O-incorporated 
cellulose acetate was challenged with Gram-positive and Gram-negative 
microorganisms, demonstrating a 4 and 5 log reduction of S. aureus and E. coli 
respectively following 24 hours irradiation with white light.  This has the potential to 
be used as an operating surface coating or wall paint to reduce the spread of 
nosocomial infection.  Further work by the same group involved incorporation of 
toluidine blue O or methylene blue into polyurethane and polysiloxane polymers by a 
swell-shrink method, in the presence and absence of gold nanoparticles, to achieve 
high photosensitiser loading [152, 153].  Promising microbial reductions of greater 
than 3 log were observed, with a further augmentation of approximately 0.5 log in the 
presence of gold nanoparticles.  Although the photosensitiser was incorporated by 
physical means, leaching from the material was not noted. 
 
Funes et al. investigated the substitution patterns of cationic porphyrin derivatives, 
and applied this knowledge to the electrochemical generation of polymeric films 
composed of porphyrin units [154].  The porphyrin, 5,10.15,20-tetra(4-N,N-
diphenylaminophenyl)porphyrin, was used alone or complexed with palladium (II) 
chloride (Pd(II)) to enhance its photodynamic action, and is shown in Figure 6.   
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Figure 6.  The porphyrin used by Funes et al. in the development of a porphyrin-
containing antimicrobial film  [154]. 
 
 
A 3 log reduction in E. coli viable count was noted following 30 minutes irradiation, 
with an approximately 2 log reduction in C. albicans viable count after the same 
period.  There did not appear to be a significant difference between the complexed 
and uncomplexed porphyrin.  The results obtained demonstrate the potential use of 
such films to inactivate microorganisms in liquid suspensions.  It also highlights the 
need to continue to expand the range of photosensitisers being used. 
 
Photosensitiser dyes bound to silica have also been studied, with modest success, 
primarily for applications in disinfection of blood and blood products [155], thus 
avoiding the challenge of removal of water-soluble photosensitisers from the medium 
following the photodisinfection procedure. 
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5-(4-carboxyphenyl)-10,15,20-tris(4-methylphenyl)porphyrin has been incorporated 
into polysilsesquioxane polymer films and challenged with Candida albicans, 
achieving a 2.5 log reduction in viable count following 60 minutes of irradiation.  
This was substantially lower than that achieved elsewhere with cationic porphyrins in 
solution, however it does provide further demonstration of the anti-fungal properties 
of immobilised porphyrins.  The proposed application of the films was 
decontamination of biological fluid or in the formation of antifungal surfaces in 
healthcare settings [156].  The log reductions in viable count are not sufficient for 
effective decontamination of surfaces or fluids, but it is possible that the use of a 
different photosensitiser, or a photosensitiser combination, may enable the design and 
fabrication of a film for use as a broad spectrum antimicrobial surface for application 
in healthcare facilities. 
 
Other studies on photosensitiser immobilisation include grafting of cellulose fabric 
with porphyrin for use as a photobactericidal textile, although the reductions achieved 
in S. aureus and E. coli viable counts were modest [157].  A more recent study by 
Arenbergerova et al. [158] built on previous work by the same group [159] to develop 
porphyrin-doped electrospun nanofibre polyurethane textiles for use as wound 
coverings for leg ulcers.  Light from a white fibre optic source was applied twice 
daily.  The clinical study demonstrated a significant reduction in wound bacterial 
burden at day 28 and 42, and a decrease in wound size and wound-related pain in 
comparison to controls.  This may provide an alternative to the topical application of 
antiseptics and antibiotics, to which resistance may develop.  
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A number of studies have been carried out employing immobilised photosensitisers 
for use in water decontamination [160-163], and for decontamination of food 
packaging and preparation surfaces [83, 164], however it is feasible that such systems 
could be transferred to biomedical and pharmaceutical applications.   
 
3.3.2.2.2.  Immobilisation on nano-scale polymers 
 
Nanotechnology is a growing area, with innumerable potential applications.  A 
growing number of studies involving photosensitisers demonstrates the breadth of 
potential.  Porphyrin-cellulose nanocrystals, structure shown in Figure 7, following 30 
minutes visible light illumination have demonstrated 5-6 log reductions in viable 
count of methicillin-resistant S. aureus, and multidrug-resistant Acinobacter 
baumannii [165].   
 
 
Figure 7.  The structure of antibacterial porphyrin-cellulose nanocrystals developed by 
Carpenter et al. [165]. 
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Only an approximately 2.5 log reduction of P. aeruginosa was achieved, which 
alongside observation of the previous results with E. coli [166] may suggest that this 
is a less effective strategy against Gram-negative bacteria, however the results are 
promising and display potential as an effective alternative to conventional 
antibacterial treatments.  
 
Rose Bengal-functionalised chitosan nanoparticles have been studied for elimination 
of bacteria in the root canal, demonstrating significant efficacy against Enterococcus 
faecalis in the presence of tissue inhibitors following irradiation at 540 nm, owing to a 
combination of 1O2 and the inherent anti-adherent properties of the positively charged 
material [167].  Further studies demonstrated anti-biofilm activity, with an additional 
benefit of dental collagen stabilisation [168], highlighting the potential clinical 
relevance of this system. 
 
These studies firmly demonstrate the ability of photosensitisers to mediate 
photodynamic inactivation of microorganisms when incorporated into a number of 
materials, whether by covalent or non-covalent bonding, and highlight the potential 
for use as broad-spectrum antibacterial systems for prevention or treatment of 
infection.  Whilst the studied nanoparticulate systems may provide a high surface area 
for 1O2 generation, this may be difficult to reproduce for medical device polymers, for 
example.  Therefore, the potential applications of immobilised polymers are 
dependent on the carrier onto which they are attached, or in which they are contained.  
Regardless of the carrier, it is anticipated that research in the area of immobilised 
photosensitisers will continue to grow and reach a clinical level, whereby infection 
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resistant materials can become an integral part of the wider infection control 
procedures in healthcare settings. 
 
3.4.  Photocatalytic disinfection 
 
Whilst not employing photosensitisers for their action, the related area of 
photocatalysis must be mentioned for completeness.  The most frequently-used 
photocatalyst is TiO2, an inexpensive nontoxic, chemically stable semiconductor 
catalyst with high photostability.  Absorption of a photon of light leads to electron 
promotion from the valence to the conduction band, leaving a positively charged hole 
in the valence band.  The photogenerated hole and electron can act as oxidation and 
reduction species respectively, leading to the generation of hydroxyl and 
hydroperoxyl radicals, and H2O2.   Three main polymorphs of TiO2 exist: anatase, 
rutile and brookite.  Anatase has been shown to be the most effective, and has a 
longer lifetime than the rutile form.  The energy required for electron promotion, the 
band gap energy, allows UVA activation of anatase photocatalysis (below ~385 nm)  
[169].  Reactive oxygen species-mediated membrane and cell wall damage, involving 
lipid peroxidation and leakage of cellular components  [170], appears to be the main 
mechanism of bactericidal action, and it and has been shown to lead to complete cell 
mineralisation [171].  A number of bacterial, fungal, protozoal, algal, and viral strains 
have been shown to be killed by TiO2 photocatalytic disinfection, an extensive list of 
which has been published by Foster et al. (2011) [169].  In order to shift the band 
onset of TiO2 to allow activation in the visible light range, metal ions have been 
doped into the structure.  Those studied include Ag and Cu, which have antimicrobial 
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effects that act in synergy with those of TiO2, and a number of other transition metals, 
as reviewed by Liou and Chang [172].   
 
A number of TiO2 immobilised self-cleaning antimicrobial surfaces have been 
developed such as urinary catheters [174, 175] and orthodontic wires [176, 177], in 
addition to decontamination of drinking water [178, 179].  For a thorough review of 
antimicrobial applications of photocatalytic disinfection, readers are referred to 
Gamage and Zhang (2010) [180].  The photocatalytic antimicrobial effect of a TiO2 
nanocomposite has recently been shown to persist for up to two hours following 
removal of the UV light source [173].  This may open new avenues for research and 
application of TiO2 materials for antimicrobial purposes where application of a 
constant light source is impractical.   
 
 
4. Conclusions 
 
Substantial advances have been made in the application of photosensitisers to the 
treatment of human disease and infection, and the ability to excite with light in the 
visible range provides a number of advantages.  The current commercial use and 
clinical efficacy of a number of systems highlights the relevancy of research on these 
compounds and associated delivery systems.  Whilst the majority of success for both 
photodynamic therapy, and photodynamic antimicrobial chemotherapy has been seen 
with ALA, and photosensitisers of the porphyrin and phenothiazinium class, current 
research with other compounds suggests that future clinical applications may be 
afforded from a wider range of sensitisers, both free and immobilised onto bulk and 
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nano-scale polymeric systems, thus expanding the potential applications for 
photosensitising compounds, particularly in the area of antimicrobials. 
 
5. Expert Opinion 
 
The use of light with photosensitisers provides a means by which treatment can be 
highly controlled in terms of time, space, and duration.  This allows tailoring of 
cancer treatments and antimicrobial strategies.  In terms of antimicrobial action, the 
multiplicity of targets in the microbial cell, and demonstrated lack of resistance 
despite attempts to induce it, confer a great benefit over conventional antimicrobial 
methods and disinfectants.  Given the findings of the recent WHO report [68], 
highlighting the global problem of antibiotic resistance, the potential of 
photosensitiser-mediated systems is therefore of significance.  Particularly, WHO 
highlighted E. coli antibiotic resistance, associated with urinary tract infections, high 
levels of methicillin resistance in S. aureus, and resistance to the last resort 
(carbapenem) treatment for Klebsiella pneumonia, often associated with hospital-
acquired pneumonia.  As prevention is often a preferable strategy to cure, 
photosensitising systems such as those described show significant promise for 
infection prevention.  While the existing clinical strategies employing photosensitisers 
have already shown great efficacy, and are of great utility in the treatment of a 
number of conditions, they are somewhat limited due to the currently narrow range of 
photosensitisers used, and the use of photosensitisers mostly in solution. A current 
goal in the field is to expand the range of indications for PDT, and this may be 
enabled by the development of new photosensitiser constructs capable of enhanced 
tissue targeting, or which can be activated by longer wavelengths of light in two-
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photon processes, allowing deeper tissue penetration and fewer side effects, 
particularly in damage to healthy tissue, and also antimicrobial treatment of tissue 
areas not normally directly accessible to light. 
 
It is anticipated that, with the synthesis of newer generation photosensitisers, and 
design of novel delivery strategies and carriers, the clinical applications of 
photosensitisers will further expand to the prevention and treatment of infection, and 
will be of significance in at least partially addressing the wider global issue of 
bacterial resistance.  Their use holds the potential to reduce or replace the use of 
conventional surface decontamination methods, and of antibiotics for some infections.  
Alongside this, however, as with any antimicrobial strategy, is the necessity to assess 
the continuing evasion of bacterial resistance to provide continued assurance of the 
superiority of these compounds over conventional treatments. 
 
Movement towards surface immobilisation has opened and will continue to open 
avenues for treatment of hospital-associated infections, related both to those carried 
on hospital surfaces and on medical devices.  By providing a means by which 
bactericidal action can be exerted, without the requirement for uptake of the 
photosensitiser, the issue of surface contamination and biofouling can be addressed.  
The experimental microbial reductions seen with immobilised photosensitisers are 
significant, and hold promise for the development of clinically useful devices and 
surfaces.  It is likely that with continued research to achieve optimal loading 
concentrations and light doses, and therefore singlet oxygen generating efficiency, a 
number of such photosensitiser-incorporated materials and medical devices will be 
developed for clinical testing over the coming years.  These will have the potential to 
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revolutionise device use, with only light being required for persistent 
decontamination, and enabling prevention of surface colonisation before infection can 
result.  Bringing together the fields of polymer and material science with 
photosensitiser design and development will allow fabrication of novel and diverse 
materials, with efficacy resulting both from optimal material properties and optimal 
photosensitising efficiency.  Application of light of multiple wavelengths may allow 
stimulation of different photosensitiser classes on one device, or indeed allow the 
combination of photocatalysis with photosensitiser-mediated antimicrobial therapies.  
The future of light-activated photosensitiser research is therefore undoubtedly bright, 
and is likely to produce clinically beneficial applications in this growing field.  
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